IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer

This trial is testing a drug called IN10018 in combination with standard chemotherapy in women with high-grade serous ovarian, fallopian tube, or peritoneal cancer that has come back after being treated with platinum-based chemotherapy. **You may be eligible if...** - You are a woman 18 or older with confirmed high-grade serous ovarian, fallopian tube, or primary peritoneal cancer - Your cancer is platinum-resistant (it returned 1–6 months after completing at least 4 cycles of platinum-based therapy) - You have received no more than 5 prior lines of treatment - You have at least one measurable tumor on imaging - You are in good physical condition (ECOG 0–1) **You may NOT be eligible if...** - Your cancer is a different subtype (not high-grade serous) - You have active brain metastases - You have had prior FAK inhibitor therapy - You are pregnant or breastfeeding - You have significant organ dysfunction Talk to your doctor to see if this trial is right for you.